Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Московский медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1 apavlichenko76@gmail.com
Список исп. литературыСкрыть список 1. Andreasen NC, Liu D et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170 (6): 609–15. 2. Borison RL, Diamond BI, Sinha D et al. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988; 24 (2): 260–3. 3. Emsley R, Nuamah I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 2012; 138 (1): 29–34. 4. Emsley R. On discontinuing treatment in schizophrenia: a clinical conundrum. NPJ Schizophr 2017; 3: 4. 5. Faber G, Smid HG, Van Gool AR et al. Neurocognition and recovery in first episode psychosis. Psychiatry Res 2011; 188 (1): 1–6. 6. Gaebel W, Riesbeck M et al. Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: Results of the first-episode study within the German research network on schizophrenia. Schizophr Res 2016; 170 (1): 168–76. 7. Galderisi S, Rossi A et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry 2014; 13 (3): 275–87. 8. Harrow M, Jobe TH et al. Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull 2013; 39 (5): 962–5. 9. Hori H, Noguchi H et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006; 86 (1–3): 138–46. 10. Husa AP, Moilanen J. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Res 2017; 247: 130–8. 11. Lehmann HE. Psychopharmacological treatment of schizophrenia. Schizophr Bull 1975; (13): 27–45. 12. Leucht S, Tardy M et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379 (9831): 2063–71. 13. Lieberman JA, Stroup TS et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209–23. 14. Lu ML, Pan JJ et al. Metoclopramide-induced supersensitivity psychosis. Ann Pharmacother 2002; 36 (9): 1387–90. 15. Mizrahi R, Kiang M et al. The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. Schizophr Res 2006; 88 (1–3): 111–8. 16. Moilanen J, Huhtaniska S et al. Brain morphometry of individuals with schizophrenia with and without antipsychotic medication – The Northern Finland Birth Cohort 1966 Study. Eur Psychiatry 2015; 30 (5): 598–605. 17. Moilanen J, Haapea M et al. Long-term antipsychotic use and its association with outcomes in schizophrenia – the Northern Finland Birth Cohort 1966. Eur Psychiatry 2016; 36: 7–14. 18. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006; 114 (1): 3–13. 19. Moncrieff J. Questioning the 'neuroprotective' hypothesis: does drug treatment prevent brain damage in early psychosis or schizophrenia? Br J Psychiatry 2011; 198 (2): 85–7. 20. Moncrieff J. Antipsychotic Maintenance Treatment: Time to Rethink? PLoS Med 2015; 12 (8). 21. Morant N, Azam K et al. The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample. J Ment Health 2017: 1–7. 22. Murray-Thomas T, Jones ME, Patel D et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol 2013; 2013: 247486. 23. Priebe S. Antipsychotic can be discontinued if patients are in remission. Eur Psychiatry 2017; 41 (S): S1. 24. Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360 (3): 225–35. 25. Royal College of Psychiatrists. Report of the Second Round of the National Audit of Schizophrenia (NAS) 2014. London: Healthcare Quality Improvement Partnership, 2014. 26. Suppes T, Baldessarini RJ et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48 (12): 1082–8. 27. Takeuchi H, Suzuki T et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull 2013; 39: 993–8. 28. Torniainen M, Suvisaari J et al. Cognitive impairments in schizophrenia and schizoaffective disorder: relationship with clinical characteristics. J Nerv Ment Dis 2012; 200 (4): 316–22. 29. Veijola J, Guo J et al. Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS One 2014; 9 (7). 30. Viguera AC, Baldessarini RJ, Hegarty JD et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54 (1): 49–55. 31. Wunderink L, Nienhuis FJ, Sytema S et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68 (5): 654–61. 32. Wunderink L, Nieboer RM, Wiersma D et al. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial. 33. Zipursky RB, Reilly TJ, Murray RM. The Myth of Schizophrenia as a Progressive Brain Disease. Schizophr Bull 2012.